Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease - Startin, Carla M.; Ashton, Nicholas J.; Hamburg, Sarah; Hithersay, Rosalyn; Wiseman, Frances K.; Mok, Kin Y.; Hardy, John; Lleó, Alberto; Lovestone, Simon; Parnetti, Lucilla; Zetterberg, Henrik; Hye, Abdul; et al. (Alzheimer's research & therapy, 2019)
Keywords: 1984; Adult; adults; Advertising executives; Age; Aged; Aging; Alzheimer Disease - blood; Alzheimer Disease - genetics; Alzheimer's disease; Amyloid; Amyloid beta-Peptides - blood; Amyloid beta-protein; Apolipoproteins E - genetics; association; beta; Biological markers; Biomarker; Biomarkers; Biomarkers - blood; Blood plasma; children; Chromosomes; cognitive decline; Composition; concentrations; Cytokines; Cytokines - blood; Dementia; Development and progression; Disease susceptibility; Down syndrome; Down Syndrome - blood; Down Syndrome - genetics; Female; follow-up; Genes; Genetic aspects; Genetic research; Health aspects; Humans; Immune system; inflammatory cytokines; Interleukin 1; Interleukins; khann g; Male; Medical research; Middle Aged; neurofilament light; neurology; Neurosciences; Neurosciences & Neurology; Neurovetenskaper; Oxidative stress; p939; Pathology; Peptides; Plasma; Proteins; risk; Risk factors; Tau; Tau proteins; tau Proteins - blood; Testing; v34; Young Adult; Plasma; Biomarker; Alzheimer’s disease; Cytokines; Interleukin 1β; Tau; Amyloid; Down syndrome; Dementia